The treatment of chronic viral hepatitis

New England Journal of Medicine

Volumn 336, Issue 5, 1997, Pages 347-

  Hoofnagle, Jay H ^a,c   Di Bisceglie, Adrian M ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; FAMCICLOVIR; FOSCARNET; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS DELTA ANTIGEN; LAMIVUDINE; LEVAMISOLE; PREDNISONE; RIBAVIRIN; SURAMIN; THYMOSIN; VIDARABINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DELTA AGENT HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HEPATITIS D; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; REMISSION INDUCTION;

EID: 1842291578     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701303360507     Document Type: Review

References (106)

1. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-55.
2. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994;20:1442-9.
3. Belle SH, Beringer KC, Detre KM. Liver transplantation in the United States: results from the National Pitt-UNOS Liver Transplant Registry. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1994. Los Angeles: UCLA Tissue-Typing Laboratory, 1994:19-35.
4. Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342:1335-40.
5. Houghton M, Choo Q-L, Kuo G, et al. The hepatitis C virus: genetic organization, persistence, and vaccine strategies. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994:33-7.
6. Hoofnagle JH. Type D (delta) hepatitis. JAMA 1989;261:1321-5. [Erratum, JAMA 1989;261:3552.]
7. Linnen J, Wages J Jr, Zhang-Keck Z-Y, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-8.
8. Muerhoff AS, Leary TP, Simons JN, et al. Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis. J Virol 1995;69:5621-30.
9. Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991;11:73-83.
10. Kuhns MC. Monitoring hepatitis B virus replication. J Hepatol 1990; 11:Suppl 1:590-4.
11. Urdea MS. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV and HIV. Clin Chem 1993;39:725-6.
12. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
13. Lau D, Kleiner DE, Park Y, Vergalla J, Hoofnagle JH. Long-term follow up of patients with chronic hepatitis B treated with alpha interferon. Hepatology 1995;22:Suppl:325A. abstract.
14. Alexander GJM, Brahm J, Fagan EA, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987;2:66-9.
15. Hoofnagle JH, Peters MG, Mullen KD, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-25.
16. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
17. Lok ASF, Wu P-C, Lai C-L, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
18. Di Bisceglie AM, Fong T-L, Fried MW, et al. A randomized controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
19. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
21. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994;39:241-75.
22. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha-interferon in Chinese HBsAg-carrier children. Lancet 1987;2:877-80.
23. Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-α in children with chronic hepatitis B. Hepatology 1991;13:1035-9.
24. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989;10:198-202.
25. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interteron-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992;15:584-9.
26. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995;1:7-15.
27. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995;109: 540-6.
28. Marcellin P, Boyer N, Colin JF, et al. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993;34:Suppl 2:S106.
29. Wright HI, Gavaler JS, Van Theil DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-4.
30. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-21.
31. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-16.
32. 1 treatment of chronic hepatitis B: a multicenter, randomized, placebo-controlled double blind study. Gastroenterology 1995;108: Suppl:A1127. abstract.
33. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
34. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995; 95:341-9.
35. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995;23:98-101.
36. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992; 267:12436-9.
37. von Weizsäcker F, Blum HE, Wands JR. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992;189:743-8.
38. Boker KH, Ringe B, Kruger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994;57:1706-8.
39. Doong S-L, Tsai CH, Schinazi RF, Liotta DC, Cheng Y-C. Inhibition of the replication of hepatitis B virus in vitro by 2́,3́-dideoxy-3́-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88: 8495-9.
40. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
41. Dienstag JL, Schiff ER, Gitlin N, et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996;24:Suppl:188A. abstract.
42. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
43. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-α in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991;13:1052-6.
44. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94.
45. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
46. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340:697-8.
47. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic and histologic features. Ann Intern Med 1995;123:330-7.
48. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327: 1906-11.
49. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
50. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
51. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.
52. Nolte FS, Thurmond C, Fried MW. Preclinical evaluation of AMPLI-COR hepatitis C virus test for detection of hepatitis C virus RNA. J Clin Microbiol 1995;33:1775-8.
53. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;315:1575-8.
54. Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-4.
55. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15:1013-6.
56. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
57. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
58. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7
59. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
60. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
61. Papo T, Marcellin P, Bernuau T, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992;116:51-3.
62. Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-α in chronic hepatitis C. Lancet 1993;342:1208-9.
63. Marcellin P, Boyer N, Degott C, et al. Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver 1994;14:302-7.
64. Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 1996;124:1058-60.
65. Ryff J-C. Usefulness of interferon for treatment of hepatitis C. J Hepatol 1995;22:Suppl 1:101-9.
66. Craxi A, Di Marco V, Lo Iacono O, et al. Lymphoblastoid α-interferon for post-transfusion chronic hepatitis C: a randomized trial of 6 vs. 12 months treatment. J Hepatol 1992;16:Suppl 1:S8. abstract.
67. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
68. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994;19:280-5.
69. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trial. J Hepatol 1995;23:487-96.
70. Alberti A, Chemello L, Bonetti P, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17:Suppl 3:S123-S126.
71. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
72. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
73. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996;24:1034-40.
74. Bacon BR, Farrell G, Benhamou JP, et al. Lymphoblastoid interferon improves long-term response to a six month course of treatment when compared with recombinant interferon alfa 2b: results of an international trial. Hepatology 1995;22:Suppl:152A. abstract.
75. Simon DM, Gordon SC, Kaplan MM, et al. Natural alfa interferon (Alferon N) treatment of chronic hepatitis C in previously untreated patients. Hepatology 1995;22:Suppl:151A. abstract.
76. Tong MJ, Blatt LM, Klein M, Manyak C, Poulakos J, Sayadzadeh K. Long-term follow-up of chronic hepatitis C virus infected patients treated with consensus interferon. Gastroenterology 1995;108:Suppl:A1188. abstract.
77. Habersetzer F, Marcellin P, Boyer N, et al. Recombinant interferon beta for the treatment of chronic hepatitis C. Hepatology 1995;22:Suppl: 119A. abstract.
78. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994;19: 1088-94.
79. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
80. Nousbaum J-B, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995;122:161-8.
81. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-4.
82. Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-30.
83. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96:224-30.
84. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon-α therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-5.
85. Mahaney K, Tedeschi V, Maertens G, et al. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994;20:1405-11.
86. Omata M, Yokosuka O, Takano S, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-5.
87. Alberti A, Chemello L, Belussi P, et al. Outcome of acute hepatitis C and role of alpha interferon therapy. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994: 604-6.
88. Viladomiu L, Genescà J, Esteban JI, et al. Interferon-α in acute post-transfusion hepatitis C: a randomized, controlled trial. Hepatology 1992; 15:767-9.
89. Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-α 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
90. Hwang S-J, Lee S-D, Chan C-Y, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:831-6.
91. Serfaty L, Chazouillères O, Pawlotsky J-M, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996;110: 291-5.
92. Ruiz-Moreno M, Rua MJ, Castillo I, et al. Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study. Hepatology 1992;16:882-5.
93. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
94. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330: 751-6.
95. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165:723-6.
96. Féray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995;22:1084-9.
97. Marcellin P, Boyer N, Pouteau M, Benhamou JP, Erlinger S. Retreatment with interferon-α of chronic hepatitis C virus infection. Lancet 1994; 344:690-1.
98. Fong T-L, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196-9.
99. Di Bisceglie AM, Shindo M, Fong T-L, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-54.
100. Bodenheimer HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1994;20:Suppl:207A. abstract.
101. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
102. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
103. Chemello L, Cavalletto L, Bernardinello E, et al. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes. J Hepatol 1994;21:Suppl 1:S12. abstract.
104. Lai MY, Yang PM, Kao JH, Wang JT, Lee HS, Chen DS. Combination therapy of α-interferon and ribavirin in patients with chronic hepatitis C: an interim report. Hepatology 1993;18:Suppl:93A. abstract.
105. Reichard O, Norkrans G, Frydén A, et al. Interferon-alpha and ribavirin versus interferon-alpha alone as therapy for chronic hepatitis C - a randomized double-blind placebo-controlled study. Hepatology 1996;24: Suppl:356A. abstract.
106. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-55.